Company Filing History:
Years Active: 2019
Title: Leyuan Ma - Innovator in Chronic Myelogenous Leukemia Treatment
Introduction
Leyuan Ma is a prominent inventor based in Holden, MA (US). He has made significant contributions to the field of medicine, particularly in the treatment of chronic myelogenous leukemia (CML). His innovative approaches have the potential to improve the lives of many patients suffering from this condition.
Latest Patents
Leyuan Ma holds a patent for methods of treating chronic myeloid leukemia (CML). This patent focuses on combination treatments, specifically targeting BCR-ABL inhibitor imatinib mesylate (IM)-resistant CML. The methods involve using a combination of a BCR-ABL inhibitor, such as imatinib, and a MEK inhibitor, like trametinib. This innovative approach aims to enhance treatment efficacy for patients who do not respond to standard therapies.
Career Highlights
Leyuan Ma is affiliated with the University of Massachusetts, where he conducts research and develops new treatment methodologies. His work has garnered attention in the medical community, highlighting his commitment to advancing cancer treatment options.
Collaborations
Leyuan Ma collaborates with notable professionals in his field, including Michael R. Green. Their joint efforts contribute to the ongoing research and development of effective therapies for chronic myelogenous leukemia.
Conclusion
Leyuan Ma's contributions to the treatment of chronic myelogenous leukemia exemplify the impact of innovative thinking in medicine. His work continues to pave the way for improved patient outcomes and advances in cancer treatment.